Antiemetics

AREA 52's Award Winning Delta 8 Carts Now Back in Stock

Retrieved on: 
Monday, April 19, 2021
Psychoactive drugs, Euphoriants, Appetite stimulants, Entheogens, Tobacco, Smoking, Electronic cigarettes, Antiemetics, Tetrahydrocannabinol, Cannabis, Electronic cigarette

Area 52 also sells gummies that pack a healthy dose of 25 mg of hemp-derived delta8 in assorted fruity flavors.

Key Points: 
  • Area 52 also sells gummies that pack a healthy dose of 25 mg of hemp-derived delta8 in assorted fruity flavors.
  • The gummies are vegan, non-GMO, gluten-free and low in sugar.\nThere\'s also one product that is grabbing delta 8 THC aficionados by the throat the Area 52 delta 8 vape cartridge .
  • Ranked the best delta 8 cart by Observer and Daily CBD , this vape liquid contains pure delta 8 THC distillate combined with strain-specific terpenes.
  • It is twice less potent than delta 9 and doesn\'t cause uncomfortable side effects such as anxiety and paranoia.

Improving Quality of THC-Based Medications Proving to be Lucrative Path for Cannabis Companies

Retrieved on: 
Thursday, April 15, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Appetite stimulants, Antiemetics, Drugs, Branches of biology, Cannabis, Medical cannabis, Tetrahydrocannabinol, Effects of cannabis

"The increasing awareness among patients as well as healthcare professionals regarding the benefits of medical marijuana has compelled the regulatory authorities to consider and legalize medical cannabis.

Key Points: 
  • "The increasing awareness among patients as well as healthcare professionals regarding the benefits of medical marijuana has compelled the regulatory authorities to consider and legalize medical cannabis.
  • THC-based medications are also noted to act as appetite stimulators in cases with wasting syndrome caused owing to AIDS.
  • All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Improving Quality of THC-Based Medications Proving to be Lucrative Path for Cannabis Companies

Retrieved on: 
Thursday, April 15, 2021
Entheogens, Euphoriants, Medicinal plants, Psychoactive drugs, Appetite stimulants, Antiemetics, Drugs, Branches of biology, Cannabis, Medical cannabis, Tetrahydrocannabinol, Effects of cannabis

"The increasing awareness among patients as well as healthcare professionals regarding the benefits of medical marijuana has compelled the regulatory authorities to consider and legalize medical cannabis.

Key Points: 
  • "The increasing awareness among patients as well as healthcare professionals regarding the benefits of medical marijuana has compelled the regulatory authorities to consider and legalize medical cannabis.
  • THC-based medications are also noted to act as appetite stimulators in cases with wasting syndrome caused owing to AIDS.
  • All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.
  • You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements.

Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education

Retrieved on: 
Tuesday, April 13, 2021
Health sciences, Antiemetics, Medical cannabis, Pharmaceuticals policy, Pharmacognosy, Pharmaceutical sciences, Branches of biology

Khiron Academy will be made available to prescribers in the UK that have registered with Cellen\'s MedCanHub, an emerging education portal.

Key Points: 
  • Khiron Academy will be made available to prescribers in the UK that have registered with Cellen\'s MedCanHub, an emerging education portal.
  • With Khiron Academy\'s CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products.
  • "\nEric Bystrom, CEO of Cellen commented, "We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK.
  • Khiron is a clear global leader in medical cannabis education.

Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK's Cellen Therapeutics to Improve Clinician Education

Retrieved on: 
Tuesday, April 13, 2021
Health sciences, Antiemetics, Medical cannabis, Pharmaceuticals policy, Pharmacognosy, Pharmaceutical sciences, Branches of biology

Khiron Academy will be made available to prescribers in the UK that have registered with Cellen\'s MedCanHub, an emerging education portal.

Key Points: 
  • Khiron Academy will be made available to prescribers in the UK that have registered with Cellen\'s MedCanHub, an emerging education portal.
  • With Khiron Academy\'s CPD accreditation and through our strategic partnership with Cellen Therapeutics, we are positioned to reach a growing number of medical professionals, and in turn, provide patients with greater access to medical cannabis products.
  • "\nEric Bystrom, CEO of Cellen commented, "We are pleased to be joining forces with Khiron on educating prescribing specialists in the UK.
  • Khiron is a clear global leader in medical cannabis education.

Bazelet Oglesby enters the Georgia cannabis market with its patented, THC free Panakeia plants

Retrieved on: 
Friday, April 16, 2021
Psychoactive drugs, Entheogens, Euphoriants, Medicinal plants, Drugs, Branches of biology, Appetite stimulants, Antiemetics, Cannabis, Tetrahydrocannabinol, Medical cannabis, Hemp

The site is one of several in Georgia that the Company will utilize to produce its 2021 Panakeia crop.\nPanakeia is the first (USPTO) patented cannabis plant in the world.

Key Points: 
  • The site is one of several in Georgia that the Company will utilize to produce its 2021 Panakeia crop.\nPanakeia is the first (USPTO) patented cannabis plant in the world.
  • Panakeia plants contain 0.00% Tetrahydrocannabinol (THC) an illegal substance under federal law that is found in all marijuana and hemp plants.
  • Panakeia plants have the most promising of all cannabinoids for broad use in food, drug and cosmetic applications.
  • We are honored and accept with responsibility, that we are part of authoring its history and excited to serve the Georgia market."

MediPharm Labs Completes Its First High THC Cannabis Oil Export to Peru

Retrieved on: 
Thursday, April 8, 2021
Psychoactive drugs, Appetite stimulants, Entheogens, Euphoriants, Antiemetics, Medicinal plants, Drugs, Branches of biology, Cannabis, Tetrahydrocannabinol, Medical cannabis, Effects of cannabis

This first import into Peru demonstrates the versatility of our GMP certified platform that qualifies MediPharm Labs to export high THC and CBD formulated oils into international medical markets where cannabis is regulated like other pharmaceutical products, said Keith Strachan, President and Interim Chief Executive Officer, MediPharm Labs.

Key Points: 
  • This first import into Peru demonstrates the versatility of our GMP certified platform that qualifies MediPharm Labs to export high THC and CBD formulated oils into international medical markets where cannabis is regulated like other pharmaceutical products, said Keith Strachan, President and Interim Chief Executive Officer, MediPharm Labs.
  • MediPharm Labs pre-formulated cannabis concentrate will be distributed to patients through compounding pharmacies in Peru that will complete final formulation and fill to exact prescription specification.
  • Since Perus initial cannabis legalization, patients have predominantly had accessed to CBD in the absence of a steady supply of legal THC.
  • MediPharm Labs is creating footholds in pharmaceutical, medical and wellness markets around the world including Australia, New Zealand, Germany, Denmark, U.K., Peru and Brazil.

ENTEXS Launches Groundbreaking THC Remediation Technology

Retrieved on: 
Wednesday, April 7, 2021
Euphoriants, Entheogens, Appetite stimulants, Psychoactive drugs, Drugs, Antiemetics, Medicinal plants, Branches of biology, Tetrahydrocannabinol, Cannabis, Hemp, Delta-8-Tetrahydrocannabinol

SACRAMENTO, Calif., April 7, 2021 /PRNewswire/ -- THC remediation is the process of removing thepsychoactive Tetrahydrocannabinol (THC) from hemp-derived extracts or products.

Key Points: 
  • SACRAMENTO, Calif., April 7, 2021 /PRNewswire/ -- THC remediation is the process of removing thepsychoactive Tetrahydrocannabinol (THC) from hemp-derived extracts or products.
  • For many consumers, however, the presence of any THC is unacceptable and producers in this category must achieve non-detectable, or "ND" levels of THC.
  • "At ENTEXS, our goal is to always be on the leading edge of remediation and extraction technologies.
  • ENTEXS' RMD-T series achieves what no other remediation system has been able to - cost-effective, very low loss-rate (

Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®

Retrieved on: 
Tuesday, April 6, 2021
Digestive diseases, Clinical medicine, Medical specialties, Chloroarenes, Antiemetics, Prolactin releasers, Dosage forms, Metoclopramide, Gastroparesis, Nasal spray

When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.

Key Points: 
  • When granted, the patent will cover methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.
  • The patent, entitled Nasal Formulations of Metoclopramide, carries a patent term to at least 2029.
  • Gimoti is Evokes nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis.
  • This new patent covers Gimoti for gastroparesis and will be listable in FDAs Orange Book.

Zynerba Pharmaceuticals to Present at the Needham Virtual Healthcare Conference

Retrieved on: 
Tuesday, April 6, 2021
Drugs, Antiemetics, Entheogens, Tetrahydrocannabinol, Cannabinoid, Neurochemistry, Psychoactive drugs

DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m.

Key Points: 
  • DEVON, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chief Executive Officer of Zynerba, will present a company overview during the 20th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021 at 1:30 p.m.
  • Investors interested in arranging a virtual meeting with the Companys management during the conference should contact the Needham conference coordinator.
  • A webcast of the presentation will be available under the Events & Webcasts tab of the Investors section of the Zynerba website at www.zynerba.com .
  • Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders.